Early Blood Test Predicts Higher MS Disability Risk Now

Credibility

Interest

Key Takeaway

A higher level of neurofilament light chain in the blood during the first year of MS is linked to greater long-term worsening of disability, and it may help decide who needs stronger treatment.

What They Found

Researchers measured a protein called serum neurofilament light chain (sNfL) in blood taken within the first year after MS symptoms started; sNfL is a sign that nerve fibers may be damaged (think of it as a smoke detector for nerve injury). Patients with sNfL above 10 pg/mL were more likely over many years to have confirmed worsening of disability and to reach an EDSS score of 3, which means noticeable walking or physical limitations (EDSS is a scale doctors use to describe disability). The study looked at patients from two separate groups and found the same pattern, which makes the finding more trustworthy. People with high sNfL who later received highly effective MS drugs had smaller risks of getting worse, suggesting treatment can change the outcome. Overall, a single early blood test seemed useful for spotting people at higher risk of future disability so doctors can consider stronger treatment sooner.

Who Should Care and Why

People newly diagnosed with MS and their caregivers should care because this blood test might show who is more likely to get worse over time, helping guide treatment choices earlier—like turning up the heat on a problem before it spreads. Neurologists and MS nurses should care because sNfL could be an extra tool, along with MRI and symptoms, to decide whether to use more powerful medicines. If your sNfL is high, it does not mean you will definitely get worse, but it means closer follow-up and talking about stronger treatments might be wise—similar to choosing a stronger umbrella when a big storm is predicted. Caregivers can use this information to plan support, appointments, and daily routines if the care team recommends closer monitoring. Patients who want to be proactive about long-term walking or function may ask their doctor about sNfL testing and what the result could mean for treatment choices.

Important Considerations

This study looked at patients not initially treated with the strongest drugs, so results may differ for people already on those medicines. A high sNfL raises risk but is not a certain prediction—some people with high levels do well and some with low levels still worsen. Tests and cutoffs (like 10 pg/mL) come from this study and might vary by lab or population, so talk with your clinician about what your specific result means.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Progression Clinical Trials

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News